Cost effectiveness of microwave thermotherapy in patients with benign prostatic hyperplasia: part I—methods

Blute, Michael L.; Ackerman, Stacey J.; Rein, Alisoh L; Beusterien, Kathleen; Sullivan, Erin; Tanio, Craig P; Strauss, Michael J.; Manyak, Michael J.

doi:10.1016/s0090-4295(00)00828-1

Cited by 45 publications

(39 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ackerman et al 217 used the standard gamble to estimate QoL values among 13 men with moderate to severe benign prostatic hyperplasia. A variety of health states were described, with the QoL impacts of severe UTIs being estimated among these.…”

Section: Quality Of Life: Adverse Eventsmentioning

confidence: 99%

See 1 more Smart Citation

Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation

Johnston

Uthman

Cummins

et al. 2017

Health Technol Assess

View full text Add to dashboard Cite

Background Most people with type 2 diabetes are overweight, so initial treatment is aimed at reducing weight and increasing physical activity. Even modest weight loss can improve control of blood glucose. If drug treatment is necessary, the drug of first choice is metformin. However, some people cannot tolerate metformin, which causes diarrhoea in about 10%, and it cannot be used in people with renal impairment. This review appraises three of the newest class of drugs for monotherapy when metformin cannot be used, the sodium–glucose co-transporter 2 (SGLT2) inhibitors. Objective To review the clinical effectiveness and cost-effectiveness of dapagliflozin (Farxiga, Bristol-Myers Squibb, Luton, UK), canagliflozin (Invokana, Janssen, High Wycombe, UK) and empagliflozin (Jardiance, Boehringer Ingelheim, Ingelheim, Germany/Eli Lilly and Company, Indianapolis, IN, USA), in monotherapy in people who cannot take metformin. Sources MEDLINE (1946 to February 2015) and EMBASE (1974 to February 2015) for randomised controlled trials lasting 24 weeks or more. For adverse events, a wider range of studies was used. Three manufacturers provided submissions. Methods Systematic review and economic evaluation. A network meta-analysis was carried out involving the three SGLT2 inhibitors and key comparators. Critical appraisal of submissions from three manufacturers. Results We included three trials of dapagliflozin and two each for canagliflozin and empagliflozin. The trials were of good quality. The canagliflozin and dapagliflozin trials compared them with placebo, but the two empagliflozin trials included active comparators. All three drugs were shown to be effective in improving glycaemic control, promoting weight loss and lowering blood pressure (BP). Limitations There were no head-to-head trials of the different flozins, and no long-term data on cardiovascular outcomes in this group of patients. Most trials were against placebo. The trials were done in patient groups that were not always comparable, for example in baseline glycated haemoglobin or body mass index. Data on elderly patients were lacking. Conclusions Dapagliflozin, canagliflozin and empagliflozin are effective in improving glycaemic control, with added benefits of some reductions in BP and weight. Adverse effects are urinary and genital tract infections in a small proportion of users. In monotherapy, the three drugs do not appear cost-effective compared with gliclazide or pioglitazone, but may be competitive against sitagliptin (Januvia, Merck Sharp & Dohme Limited, Kenilworth, NJ, USA). Funding The National Institute for Health Research Health Technology Assessment programme.

show abstract

Section: Quality Of Life: Adverse Eventsmentioning

confidence: 99%

“…Of the above papers, Ackerman et al 217 could be argued as coming closest to the NICE reference case. But the usefulness of these estimates is compromised by the small sample size.…”

Section: Ellis and Vermamentioning

confidence: 99%

Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation

Johnston

Uthman

Cummins

et al. 2017

Health Technol Assess

View full text Add to dashboard Cite

show abstract

“…Ackerman et al . [ 24 ] reported utility values in 13 men with moderate to severe BPH. A series of BPH-specifi c health states were described according to three treatments, fi ve short-term clinical events, and 17 possible long-term outcomes.…”

Section: Quality Of Life In Patients With a Utimentioning

confidence: 99%

Systematic review of the impact of urinary tract infections on health‐related quality of life

Bermingham

Ashe

2012

BJU International

View full text Add to dashboard Cite

What ' s known on the subject? and What does the study add? Values for equivalent health states can vary substantially depending on the measure used and method of valuation; this has a direct impact on the results of economic analyses. To date, the majority of existing economic evaluations that include UTI as a health state refer to an analysis in which the Index of Well Being was used to estimate the quality of life experienced by young women with UTIs. Currently, there are no validated methods or fi lters for systematically searching for the type of generic quality of life data required for decision analytic models.This study is the only systematic review of quality of life in people with UTI in the literature. Twelve studies were identifi ed which report quality of life using a variety of generic methods; the results of these papers were summarized in a way that is useful for a health researcher seeking to populate a decision model, design a clinical study or assess the effect of UTI on quality of life relative to other conditions. One research group provided previously unpublished data from a large cohort study; these scores were mapped to EuroQol 5-Dimension values using published algorithms and probabilistic simulations.The aim of this review was to identify studies that have evaluated the impact of symptomatic urinary tract infection (UTI) and UTI-associated bacteraemia on quality of life, and to summarize these data in a way that is useful for a health researcher seeking to populate a cost -utility model, design a clinical study or assess the effect of UTIs on quality of life relative to other conditions. We conducted a systematic search of the literature using MEDLINE, EMBASE, the NHS Economic Evaluations database, Health Technology Assessment database, Health Economics Evaluations database, Cost-Effectiveness Analysis Registry and EuroQol website. Studies that reported utility values for symptomatic UTI or UTI-associated bacteraemia derived from a generic QoL measurement tool or expert opinion were included. Studies using disease-specifi c instruments were excluded. Twelve studies were identifi ed that included a generic measure of health-related quality of life for patients with UTIs. These measures included: the short-form (SF)-36 and SF-12 questionnaires; the Health Utilities Index Mark 2; Quality of Well Being; the Index of Well Being, standard gamble; the Health and Activity Limitation Index; and expert opinion. The authors of studies using either of the SF questionnaires were contacted for additional data. One research group provided previously unpublished data from a large cohort study; these scores were mapped to EuroQol 5-Dimension (EQ-5D) values using published algorithms and probabilistic simulations. The present review provides health researchers with several sources from which to select utility values to populate cost -utility models. It also shows that very few studies have measured quality of life in patients with UTI using generic preference-based measures of health and none have evalua...

show abstract

“…PCa occurred in 599 patients in the dutasteride group and 782 patients in the placebo group. Ejaculatory dysfunction 0.007 [17] Impotence 0.029 [17] Hospitalization due to UTI 0.00058 [17] AUR = acute urinary retention; BPH = benign prostatic hyperplasia; PCa = prostate cancer; UTI = urinary tract infection. a Utilities for high-grade and low-grade tumors consider adverse events that may occur due to PCa treatment.…”

Section: Resultsmentioning

confidence: 99%

“…To calculate quality-adjusted life-years (QALYs) and perform cost-utility analyses, we obtained utility weights from the published literature [17][18][19] and applied these to the men within the REDUCE trial according to health status. (Data required to calculate utilities were not collected within REDUCE.)…”

Section: Utility and Quality Of Lifementioning

confidence: 99%

Economic Analysis: Randomized, Placebo-Controlled Clinical Trial of Dutasteride in Men at High Risk for Prostate Cancer

Chirila¹,

Earnshaw²,

Black³

2012

J Cancer Sci Ther

View full text Add to dashboard Cite

Objective: Given the economic burden of prostate cancer (PCa), a PCa risk-reduction medication would be desirable. A within-trial economic analysis of the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study was performed.Methods: REDUCE, a 4-year, randomized, double-blind, placebo-controlled, parallel-group clinical trial, compared efficacy and safety of dutasteride 0.5 mg daily and placebo to reduce the risk of PCa in men at increased risk. Resource use was prospectively collected; costs from standard costing sources were applied. Utilities were obtained from published literature. Relative risks and Wilcoxon rank sums were used to examine differences between treatments.Results: Placebo patients were at significantly higher risk (P < 0.05) for concomitant medication use; and health care visits related to surgical procedures, unscheduled biopsies, acute urinary retention, urinary tract infections, or macroscopic hematuria. Total costs were significantly lower (P < 0.001) in dutasteride patients ($1 300; 95% confidence interval: $806, $1 795). Incremental cost per quality-adjusted life-year (QALY) was $26 516; cost per PCa case avoided was $19. Conclusions:During the 4-year trial period, men at increased risk for PCa receiving dutasteride incurred fewer health care costs than men receiving placebo, which helped offset dutasteride costs. Dutasteride was good value for money.

show abstract

Cost effectiveness of microwave thermotherapy in patients with benign prostatic hyperplasia: part I—methods

Cited by 45 publications

References 19 publications

Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation

Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation

Systematic review of the impact of urinary tract infections on health‐related quality of life

Economic Analysis: Randomized, Placebo-Controlled Clinical Trial of Dutasteride in Men at High Risk for Prostate Cancer

Contact Info

Product

Resources

About